These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22542157)

  • 1. Aspirin and NSAIDs; benefits and harms for the gut.
    Thiagarajan P; Jankowski JA
    Best Pract Res Clin Gastroenterol; 2012 Apr; 26(2):197-206. PubMed ID: 22542157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
    Tsibouris P; Hendrickse MT; Isaacs PE
    Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
    Peura DA; Wilcox CM
    Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
    Sandler RS
    Important Adv Oncol; 1996; ():123-37. PubMed ID: 8791132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin: the balance between benefits and harms. Preface.
    Lanas A
    Best Pract Res Clin Gastroenterol; 2012 Apr; 26(2):97-9. PubMed ID: 22542148
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
    Hur C; Nishioka NS; Gazelle GS
    J Natl Cancer Inst; 2004 Feb; 96(4):316-25. PubMed ID: 14970280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical inquiries. Is aspirin effective for primary prevention of colon cancer?
    Rufner KL; Park MK; Tweed EM
    J Fam Pract; 2010 Jul; 59(7):E410c-d. PubMed ID: 20625563
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
    Dubé C; Rostom A; Lewin G; Tsertsvadze A; Barrowman N; Code C; Sampson M; Moher D;
    Ann Intern Med; 2007 Mar; 146(5):365-75. PubMed ID: 17339622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
    Wang F; Lv ZS; Fu YK
    Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal effects of aspirin.
    Sostres C; Lanas A
    Nat Rev Gastroenterol Hepatol; 2011 Jun; 8(7):385-94. PubMed ID: 21647198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
    Kraus S; Sion D; Arber N
    Curr Pharm Des; 2015; 21(35):5127-34. PubMed ID: 26369678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin as a chemoprevention agent for colorectal cancer.
    Lee CS; McNamara D; O'Morain CA
    Curr Drug Metab; 2012 Nov; 13(9):1313-22. PubMed ID: 22493984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.
    Hur C; Simon LS; Gazelle GS
    Cancer; 2004 Jul; 101(1):189-97. PubMed ID: 15222006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention in Barrett's esophagus: A pill a day?
    Jankowski JA; Hooper PA
    Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):155-70. PubMed ID: 21112505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
    Konturek PC; Kania J; Burnat G; Hahn EG
    J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
    Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
    Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
    Bresalier RS
    Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
    Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
    BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin for the prevention of colorectal cancer.
    Garcia-Albeniz X; Chan AT
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):461-72. PubMed ID: 22122763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.